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Objective
To investigate whether bipolar androgen therapy (BAT), involving rapid cyclic administration of high-dose testosterone, as
a novel treatment for metastatic castration-resistant prostate cancer (mCRPC) promotes improvements in body composition
and associated improvements in lipid proﬁles and quality of life.

Patients and Methods
Men from two completed trials with computed tomography imaging at baseline and after three cycles of BAT were
included. Cross-sectional areas of psoas muscle, visceral and subcutaneous fat were measured at the L3 vertebral level.
Functional Assessment of Chronic Illness Therapy – Fatigue questionnaire and 36-item short-form health survey were used
to assess quality of life.

Results
The 60 included patients lost a mean (SD) of 7.8 (8.2)% of subcutaneous fat, 9.8 (18.2)% of visceral fat, and gained
12.2 (6.7)% muscle mass. Changes in subcutaneous and visceral fat were positively correlated with each other (Spearman’s
correlation coefﬁcient 0.58, 95% conﬁdence interval 0.35–0.71) independent of the effects of age, body mass index, and
duration of androgen-deprivation therapy. Energy, physical function, and measures of limitations due to physical health
were all signiﬁcantly improved at 3 months. The improvements in body composition were not correlated with decreases in
lipid levels or observed improvements in quality of life.

Conclusions
In the present study, BAT was associated with signiﬁcant improvements in body composition, lipid parameters, and quality
of life. This has promising implications for the long-term health of men with mCRPC.

Keywords
prostate cancer, body composition, androgen-deprivation therapy, cancer survivorship, metastatic castration-resistant
prostate cancer, bipolar androgen therapy, #PCSM, #ProstateCancer, #uroonc

Introduction
The primary treatment for metastatic prostate cancer is
androgen-deprivation therapy (ADT), which is continued
indeﬁnitely once started [1]. The low testosterone state
induced by ADT has negative impacts on body
composition, causing an increase in body fat, a decrease in
muscle mass, and alteration of lipid proﬁles [2–4]. ADT
has been associated with a loss of ~5% of muscle mass
and a gain of up to 10% of body fat, including both
subcutaneous and visceral fat [2–4]. Furthermore, it has
been associated with increases in total cholesterol, low- and

high-density lipoprotein (LDL and HDL) levels, as well as
triglyceride (TG) levels [5]. These changes are relevant
because cardiovascular disease (CVD) is a major cause of
morbidity and mortality in men with prostate cancer and
these alterations in CVD risk factors may contribute to the
possible link between CVD and ADT [6,7]. Furthermore,
low muscle mass, i.e. sarcopenia, and high levels of
subcutaneous fat both associated with ADT, have been
associated with poor outcomes in metastatic castrationresistant prostate cancer (mCRPC), including lower
overall survival among men with advanced prostate cancer
[8–10].
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Reversing effects of ADT

Newer oral therapies in prostate cancer targeting the
androgen axis such as abiraterone, a cytochrome P450 17A
(CYP17A) inhibitor, and enzalutamide, an androgen receptor
antagonist, have improved overall survival for men with
mCRPC [11,12]. However, the addition of these agents to
ADT is further associated with negative effects on body
composition such as skeletal muscle loss and body fat
increases, which may contribute to the increased risk of CVD
in these patients [8,13–15].
Bipolar androgen therapy (BAT) is the cyclic administration
of high-dose testosterone in men who remain on long-term
LHRH agonists or antagonists [16]. The effect of this therapy
is rapid cycling between the polar extremes of
supraphysiological and near-castrate serum levels of
testosterone [16]. This strategy has been associated with
tumour responses in men with mCRPC [17,18]. We
hypothesised that this rapid cycling would also promote
improvements in body composition, lipid proﬁles, and quality
of life that would be a counter to the effects of anti-androgen
therapies.

Patients and methods
Patients
Data were pooled from two completed clinical trials at a
single institution: TRANSFORMER (NCT02286921) and
RESTORE (NCT02090114). The TRANSFORMER trial was a
randomised trial in men with progressive mCRPC after
treatment with abiraterone who received either BAT or
enzalutamide, with the option for cross-over after progression
[19]. Men treated with BAT on trial were screened for
eligibility. In both trials, 400 mg testosterone cypionate was
given intramuscularly and LHRH agonists were continued.
The RESTORE trial was a single-arm trial of men who had
progressive disease after either abiraterone or enzalutamide
and who then were treated with BAT [17,20]. Patients who
received BAT therapy prior to enrolment (n = 11), who were
not previously treated with abiraterone or enzalutamide
(n = 24), or did not have CT imaging performed within the
Johns Hopkins medical system (n = 10) were excluded.
Participants in both protocols had CT imaging at baseline
(just prior to start of BAT) and after three 28-day cycles of
BAT.
Anthropometry based on CT Image Analyses
The CT scans taken at baseline and 3 months were analysed
by three readers of varying training levels: attending
radiologist (R.G.), 2 years postgraduate level (J.T.) and second
year medical student (V.D.). All readers were blinded to
patient identity, characteristics, and study group, and to the
measurements made by the other readers. OsiriX v10.0.4
(Pixmeo Sarl, Bernex, Switzerland) software was utilised to

perform the image analysis. A slice at the L3 vertebral level,
determined by the attending radiologist, was used by all
readers to make measurements, consistent with previous
studies and because analyses here are associated with
estimates of whole body composition measurements [21].
Readers ﬁrst generated a closed polygon between the visceral
adipose layer and abdominal muscle layer and then generated
regions of interest (ROIs) using attenuation values for the
various tissue types (muscle: 30 to 150 Hounsﬁeld units
[HU], subcutaneous adipose tissue: 190 to 30 HU, and
visceral adipose tissue: 150 to 50 HU) [22]. The psoas
muscle was individually segmented using a closed polygon
around the bilateral psoas. Cross-sectional areas (cm2) of
psoas muscle, visceral adipose tissue, and subcutaneous
adipose tissue were measured using the newly created ROIs.
Inter-reader variability was calculated and the measurements
obtained by the three readers were averaged.
Measures
Lipid panels were obtained as part of the trial protocol at
start of testosterone and at 3 months after BAT treatment.
Optimal lipid parameters were deﬁned based on the National
Cholesterol Education Program/Adult Treatment Panel III
Guidelines [23]. This categorises the thresholds for optimal
LDL levels as <100 mg/dL, HDL levels >60 mg/dL, and TG
levels <150 mg/dL. HDL levels <40 mg/dL are considered
low. Sarcopenia was deﬁned as having a Skeletal Muscle
Index (SMI), based on the area of the psoas muscle at L3,
divided by the height in meters (cm2/m2) of <55 cm2/m2,
which is consistent with consensus deﬁnitions on cachexia in
patients with cancer [24]. The Functional Assessment of
Chronic Illness Therapy – Fatigue (FACIT-F) scale and the
36-item short-form health survey (SF-36) questionnaires were
used to measure fatigue, energy, physical functioning levels,
emotional well-being and limitations due to physical health at
baseline and at 3 months [25–27].
Statistical Analysis
Patient characteristics were summarised via descriptive
statistics (mean/SD or median/range for continuous variables,
and frequency/percentage for categorical variables).
Consistencies of body composition measures from three
different readers at each time point were ﬁrst assessed via
intraclass correlation coefﬁcients (ICCs). As a result of the
high yield ICC (>0.96), the mean value of body composition
measures among the three readers was utilised for each
individual patient at each time point. Changes in body
composition were summarised by the percentage change from
baseline as a way of individual normalisation. The means of
the baseline and 3-month values for the outcomes were
reported and the distributions of differences, from baseline to
3 months, were tested via paired Wilcoxon tests. Associations
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between changes of body composition measures, and the
associations between body composition changes and lipid
level changes or changes of quality-of-life outcomes were
assessed via Spearman’s correlation coefﬁcients. In addition,
linear regression models were used for testing the associations
between changes of outcomes (changes of body composition
outcomes, changes of lipid outcomes, and changes of qualityof-life outcomes) and patient characteristics (pre-speciﬁed for
patient age at baseline, body mass index [BMI], and duration
of prior ADT). The associations between changes of body
composition measures and changes of lipid outcomes with
adjustment of patient characteristics were examined via
multivariable linear regression models. The McNemar test
was used for assessing the differences in the percentage of
sarcopenic patients before and after treatment. Statistical
analyses were conducted using R, version 3.6.0 (R Foundation
for Statistical Computing, Vienna, Austria). All P values were
calculated using two-sided tests with a threshold of 0.05
signiﬁcance level.

Results
A total of 60 patients were included in the ﬁnal cohort.
Baseline patient characteristics are shown in Table 1. The
median age of the cohort was 73 years and 85% of the
patients were White. Two-thirds of the population had
localised disease at initial diagnosis, while one-third had de
novo metastatic disease. Additionally, 30% had Gleason Grade
≤7, 27% had Gleason 8 disease and 43% had Gleason 9 or 10
disease. The mean (SD) time on ADT was 4 (5.7) years. All
patients had received prior abiraterone or enzalutamide and
only three patients (5%) had received any prior
chemotherapy. The mean (SD) BMI at baseline was
29.3 (4.6) kg/m2, with 17% classiﬁed as having a normal
BMI, 43% as overweight and 40% as obese. Bone metastases
were the most common site of metastatic disease (48 patients,
80%), followed by lymph node metastases (23, 38%) and
visceral disease (three, 5%), with 13 patients having more
than one site of disease (22%). The median (interquartile
range) baseline PSA was 28.6 (9.6–68.2) ng/mL and 27 of the
patients had PSA responses (45%) during these 3 months.
There was excellent interclass concordance between the
readers for each of the measures of body composition
(Table 2 with all ICCs >0.96).

Table 1 Baseline characteristics of patients with mCRPC who were treated
with at least 3 months of BAT as second-line and later therapy on RESTORE
(n = 45) or TRANSFORMER (n = 15) (cohorts A/B).
Variable
Age at start of BAT, years, median (range)
Race, n (%)
White
Black
Other
Stage at diagnosis of prostate cancer
Localised
metastatic
Gleason score
6
7
8
9–10
Duration of prior ADT, years, mean (SD)
Year of BAT treatment, n (%)
2014–2016
2017–2018
Sites of metastatic disease, n (%)
Any bone metastases
Any lymph node metastasis
Visceral
Prior chemotherapy, n (%)
Prior abiraterone or enzalutamide, n (%)
BMI at baseline (start of BAT), kg/m2, mean (SD)
BMI (kg/m2) category at baseline (start of BAT), n (%)
<25
25–30
≥30
PSA level, ng/mL
Baseline PSA, mean (SD)
Baseline PSA, median (interquartile range)
PSA responses, n (%)
Any response (decline in PSA from baseline)
No response
Bone protective agents, n (%)
Yes
No

Value
73, (50–87)
51 (85)
5 (8)
4 (7)
40 (67)
20 (33)
2
16
16
26
4

(3)
(27)
(27)
(43)
(5.7)

44 (73)
16 (27)
48
23
3
3
60
29.3

(80)
(38)
(5)
(5)
(100)
(4.6)

10 (17)
26 (43)
24 (40)
51 (67)
29 (10–68)
27 (45)
33 (55)
29 (48)
31 (52)

Table 2 Concordance between readers in outcomes of subcutaneous
(SQ) fat, visceral (VC) fat, and muscle mass.
Outcomes
Baseline
Subcutaneous fat
Visceral fat
Muscle mass
3-month follow up
Subcutaneous fat
Visceral fat
Muscle mass

N

ICC

19
19
20

0.998
0.999
0.963

17
17
17

0.998
0.999
0.991

Body Composition
The patients lost a mean (SD) of 7.8 (8.2)% of subcutaneous
fat and 9.8 (18.2)% of visceral fat, with 83% of patients
having at least some loss of subcutaneous fat and 68% of
patients with some visceral fat loss (Fig. 1A). The mean
subcutaneous fat area was 265 cm2 at baseline, which
decreased to 245 cm2 at follow up (P value for difference
< 0.01). Mean visceral fat decreased from 233 to 213 cm2
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(P value for difference < 0.01). Neither baseline age at start of
BAT treatment nor baseline BMI inﬂuenced the degree of
change of body composition measures (all P > 0.05). The
duration of prior ADT did not impact the degree of
subcutaneous or visceral fat lost (P = 0.51 and P = 0.07).
Changes observed in subcutaneous fat were positively

© 2021 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International

Reversing effects of ADT

Fig. 1 Overview of measurements at baseline and at 3-month follow-up after BAT for (A) body composition outcomes: subcutaneous (SC) fat, visceral
(VC) fat, and muscle mass (MM); (B) lipid outcomes: LDL, HDL and TGs; (C) quality-of-life outcomes: FACIT-Fatigue scale (Facit), Energy, Physical
Functioning (Phys), Emotional well-being (Emot), and Limitations due to physical health (Limits). Red lines indicated the corresponding mean values.
Measurements from the same individual were connected with grey lines.

A

B
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LDL
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100
80
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TG
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3-month

Baseline

correlated with the changes in visceral fat (Spearman’s
correlation coefﬁcient 0.58, 95% CI 0.35–0.71) and this was
independent of effects of age, BMI, and duration of ADT.
The patients gained a mean (SD) of 12.2 (6.7)% muscle mass
in 3 months, with 97% of patients having some gain of
muscle mass. Figure 2 shows a representative analysis of the
increase in muscle mass seen with 3 months of BAT
treatment. The mean muscle area increased from 140 to
158 cm2 (P value for difference < 0.001). The duration of
ADT did have a signiﬁcant impact on the degree of muscle
mass gained (P = 0.02). Patients who had a prior duration of
ADT of <4 years gained a mean (SD) of 9.7 (6.1)% muscle
mass compared to a 14.7 (6.4)% gain of muscle mass among
men who were on ADT for ≥4 years (P for difference
= 0.003). A summary of the changes is shown in Table 3. In
total, 55 (92%) patients were sarcopenic at baseline and the
proportion of sarcopenia was signiﬁcantly lower (75%,
P = 0.004 for difference between baseline and follow-up) at
the 3-month follow-up after BAT treatment.
Lipids
The LDL levels decreased signiﬁcantly by a mean (SD) of
12.4 (19.1) mg/dL, with 74% of patients having a decrease in

3-month

Limits

100

120

75
50
25
0
Baseline

Emot

0
240

Baseline

50

50

100

160

75

Phys

100

HDL

VC

Value

400
300

Energy

200

50
40
30
20
10
100

Facit

500

300

C

200

3-month

LDL levels (P for difference < 0.001; Fig. 1B). Among the 32
patients who had baseline LDL levels above the optimal level
(≥100 mg/dL), 14 (44%) had LDL levels at follow-up that
were <100 mg/dL and in the optimal range.
The HDL levels decreased by a mean (SD) of 9.1 (11.4) mg/
dL (P for difference < 0.001; Table 3) and16% of patients
had an increase in their HDL levels (Fig. 1B). There were
only three patients who had HDL levels of <40 mg/dL at
baseline, which would be considered low. None of these
three patients had follow-up levels that were >40 mg/dL at
3 months.
The TG levels signiﬁcantly decreased by a mean (SD) of
26.9 (59.2) mg/dL (P for difference = 0.005; Table 3) with
69% of patients having some decrease in TG levels (Fig. 1B).
Of the 23 patients who had TG levels of >150 mg/dL at
baseline, 48% were within goal range, <150 mg/dL, at followup.
No associations were observed between changes of lipid
measures and patient characteristics (baseline age at start of
BAT treatment, baseline BMI and duration of ADT; all
P > 0.05). Associations between changes in visceral fat and
LDL or TG levels did not approach statistical signiﬁcance
(P = 0.09 and P = 0.92, respectively). Similarly, there was no
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Fig. 2 Image of CT abdomen at L3 vertebral level with segmentation of visceral fat (yellow area), subcutaneous fat (blue area) and abdominal wall
musculature (red area) performed manually with OsiriX at 3-month interval between the two scans (A,B).

A

B

Table 3 Summary Statistics for body composition measures and lipid parameters at baseline and at 3-month follow-up after initiation of BAT.
Baseline,
mean (SD)

Subcutaneous fat area, cm2
Visceral fat area, cm2
Muscle area, cm2
LDL, mg/dL
HDL, mg/dL
TGs, mg/dL
FACIT-F scale
Energy
Physical functioning
Emotional well being
Limitations due to physical health

265.1
233.1
140.4
102.4
59.0
146.9
39.3
56.1
66.0
81.2
56.5

(98.3)
(119.1)
(24.4))
(35.5)
(20.1)
(73.8)
(10.5)
(21.1)
(22.3)
(12.3)
(43.7)

3-month follow-up,
mean (SD)

245.0
212.5
157.5
91.6
49.7
121.3
42
64.1
70.9
84.4
73.4

% of ↑/↓ from baseline
to 3-month follow-up

(96.0)
(121.8)
(27.8)
(31.2)
(13.5)
(71.9)
(9.6)
(24.7)
(21.8)
(13.2)
(36.3)

83
68
97
74
84
69
52
63
54
54
38

↓
↓
↑
↓
↓
↓
↑
↑
↑
↑
↑

% change from
baseline to
3-month follow-up,
mean (SD)
↓ 7.8
↓ 9.8
↑ 12.2
↓ 12.4
↓ 9.1
↓ 26.9
↑ 2.11
↑ 7.8
↑ 4.2
↑ 1.8
↑ 13.9

(8.2)
(18.2)
(6.7)
(19.1)
(11.4)
(59.2)
(12.6)
(19.5)
(15.5)
(8.6)
(32.2)

P value for
difference*

<0.001
0.001
<0.001
<0.001
<0.001
0.0005
0.33
0.004
0.05
0.09
<0.001

*P values were testing the differences of outcome’s distribution between baseline and 3-month follow-up after BAT therapy via Wilcoxon signed-rank
test.

signiﬁcant association between changes in muscle mass and
changes in HDL (P = 0.61).
Quality of Life
Energy levels and physical functioning levels signiﬁcantly
improved from baseline to 3 months (P = 0.004 and P = 0.05
for change, respectively), as did limitations due to physical
health (P < 0.01) (Table 3, Fig. 1C). However, none of these
improvements were correlated with a change in muscle mass,
visceral body fat, or subcutaneous body fat. There was no
signiﬁcant change in the absolute change from baseline to
3 months on fatigue (measured by FACIT-F; P = 0.33) or
emotional well-being (P = 0.09; Table 3). While most patients
reported improvements in energy, physical functioning, and
emotional well-being, 46% (95% CI 31–61), 39% (95% CI 25–
55), 28% (95% CI 16–43) of patients respectively, reported
improvements that would be considered clinically meaningful
[28]. On average, the changes seen in limitations due to
physical health are considered clinically meaningful [28]. No
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statistically signiﬁcant associations were observed between
changes in quality of life and patient characteristics (baseline
age at start of BAT treatment, baseline BMI and duration of
ADT; all P > 0.05).

Discussion
The present study demonstrates that three cycles of BAT
therapy in patients with mCRPC is associated with signiﬁcant
positive changes in body composition, lipid proﬁles, and
measures of quality of life. Subcutaneous and visceral fat
decreased by 7.8% and 9.8% respectively, while muscle mass
increased by 12.2% on average. Additionally, LDL, HDL and
TG levels decreased with BAT therapy by 12.4, 9.1, and
26.9 mg/dL, respectively. In studies with BAT performed to
date, the duration of BAT has ranged from 1 to 60 months.
Longer-term treatment with BAT may produce an even
greater effect on body composition, although this must be
conﬁrmed in larger studies. While there did not seem to be a
signiﬁcant difference in the rate of cardiovascular thrombotic
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events in the context of the clinical trials, the long-term effect
on cardiovascular health given these changes will need to be
studied.
Although patients were analysed after only 3 months of BAT,
these ﬁndings are consistent with data from previous studies
of BAT in men with metastatic hormone-sensitive prostate
cancer, where there was an improvement in quality-of-life
scores [29]. It is also consistent with ﬁndings on
supplementation of testosterone in the non-cancer patient
population. In a meta-analysis of testosterone
supplementation, it was found that testosterone was
associated with a decrease in fat and an increase in muscle
mass [30]. Among men who were hypogonadal at baseline,
there was also an improvement seen in lipid proﬁles with
decreases in total cholesterol and TGs [30]. There have been
varying results of testosterone supplementation on older men
in the literature. In one study of 24 men with a mean (SD)
age of 57.5 (4.8) years with type 2 diabetes and visceral
obesity, oral testosterone supplementation decreased visceral
fat by 5.7% after 3 months [31]. Another study of men aged
65–85 years did not show changes in body composition with
testosterone supplementation after 12 weeks; however, the
doses used in the study (testosterone patch that delivered
5 mg testosterone over 24 h) were lower than used in other
studies and in our present study. Testosterone
supplementation in hypogonadal men has been associated
with small decreases in cholesterol, up to 5 mg/dL, with no
signiﬁcant changes in TGs [32]. In older obese men (aged
62–78 years), testosterone supplementation was associated
with a signiﬁcant decrease in LDL (13.5 mg/dL), HDL
(5.4 mg/dL) and TGs (35 mg/dL), consistent with our present
study [33]. Meta-analyses of randomised studies on the effect
of testosterone supplementation in hypogonadal men do show
consistent improvements in quality of life, in particular
energy levels, consistent with our present study [34].
There are no other therapies for prostate cancer that have
produced such results in terms of body composition and lipid
proﬁles, although some, including bone protective agents,
may improve quality of life [35]. Exercise, both resistance and
aerobic training, have had varying success in improving body
composition parameters with estimates of up to 16% increase
in muscle mass and as much as 29% loss of body fat,
although the results are quite variable [36]. Pooled analyses
have not shown a beneﬁt of exercise on lipid proﬁles in men
with prostate cancer treated with ADT [37,38].

Conclusion
BAT, a novel treatment strategy being studied for mCRPC, is
associated with signiﬁcant improvements in body
composition, lipid parameters, and a decrease in the
proportion of sarcopenic patients after 3 months of
treatment. This is the only therapy to date for the treatment

of advanced prostate cancer that is associated with these
improvements and has promising implications for the longterm health of men with mCRPC.
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